Data from GLORY global single database about the impact of this strategy in RET fusion positive NSCLC suggested a partial efficacy of the platinum combination with pemetrexed as first line (PFS 6.3 months–OS 23.6 months) [45]. The gene discussed is RET; the disease is non-small cell lung carcinoma.